BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8895596)

  • 1. In pursuit of antisense.
    Matteucci MD; Wagner RW
    Nature; 1996 Nov; 384(6604 Suppl):20-2. PubMed ID: 8895596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic oligonucleotides: the development of antisense therapeutics.
    Monteith DK; Levin AA
    Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
    Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
    Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in antisense therapeutics discovery and development.
    Crooke ST
    Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
    Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective gene inhibition using antisense oligodeoxynucleotides.
    Flanagan WM; Wagner RW
    Mol Cell Biochem; 1997 Jul; 172(1-2):213-25. PubMed ID: 9278247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S; Kandimalla ER
    Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2',5'-linked oligo-3'-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression.
    Bhan P; Bhan A; Hong M; Hartwell JG; Saunders JM; Hoke GD
    Nucleic Acids Res; 1997 Aug; 25(16):3310-7. PubMed ID: 9241246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
    Hau P; Jachimczak P; Bogdahn U
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. True antisense oligonucleotides with modified nucleotides restricted in the N-conformation.
    Koizumi M
    Curr Top Med Chem; 2007; 7(7):661-5. PubMed ID: 17430207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells.
    Hatta T; Takai K; Nakada S; Yokota T; Takaku H
    Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?
    Krieg AM; Stein CA
    Antisense Res Dev; 1995; 5(4):241. PubMed ID: 8746772
    [No Abstract]   [Full Text] [Related]  

  • 17. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An EGFR antisense oligodeoxynucleotides and its phosphorothioate analogue inhibit the growth of human hepatocarcinoma BEL-7404 cells].
    Lin JQ; Xu ZS; Zhang HY; Yang ZW; Xu YH
    Shi Yan Sheng Wu Xue Bao; 1995 Sep; 28(3):241-6. PubMed ID: 8571707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.
    Lorenz P; Misteli T; Baker BF; Bennett CF; Spector DL
    Nucleic Acids Res; 2000 Jan; 28(2):582-92. PubMed ID: 10606658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.